PTC Therapeutics Withdraws Translarna NDA After FDA Flags Weak Efficacy, Shares Slide 5%
PTC Therapeutics withdrew its New Drug Application for Translarna after the FDA flagged insufficient evidence of effectiveness in Duchenne muscular dystrophy. The decision triggered a 5.16% after-hours share decline and weighs on the Harbor US Small Cap ETF, which holds 1.89% of its assets in PTC.
1. PTC Therapeutics Pulls Translarna NDA
PTC Therapeutics withdrew its NDA resubmission for Translarna in Duchenne muscular dystrophy after FDA feedback flagged insufficient evidence of effectiveness, ending over two decades of development for the nonsense mutation therapy.
2. PTC Share Reaction
PTC Therapeutics shares fell 5.16% during after-hours trading, trading 10% below their 20-day simple moving average and facing bearish momentum indicators, reflecting investor concern over the regulatory setback.
3. Impact on HAPS ETF
Harbor Human Capital Factor US Small Cap ETF holds a 1.89% weight in PTC Therapeutics; this therapy setback applies modest downward pressure on HAPS performance but is cushioned by the ETF’s broader diversification.